Apr 19, 2010
SuppreMol Receives U.S. Orphan Drug Designation for SM101

Apr 12, 2010
SuppreMol initiates Phase Ib/IIa clinical trial with its lead candidate SM101

Feb 08, 2010
SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing

September 15-17, 2010
BioPharma America 2010, Boston, MA, USA

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources

Prof. Peter Buckel im Video-Interview

SuppreMol GmbH
Am Klopferspitz 19
82152 Martinsried/Munchen
Germany
                                                  
Tel: +49 (0)89 30 90 50 680
Fax: +49 (0)89 30 90 50 68 68

info(at)suppremol.com
www.suppremol.com

VAT-ID: DE 223991300
Handelsregister München
Commercial Register Munich: HRB 143051
CEO: Prof. Dr. Peter Buckel
Advisory Board Chairman: Dr. Thomas Hecht

Accountable for content: SuppreMol GmbH / Akampion (www.akampion.com)
Photography: action press GmbH & Co. KG (www.actionpress.de), Photographer: Goran Gajanin
Concept, Design and Realisation: JKK Jörg Krawczyk Kommunikation (www.jk-stuttgart.de)